0000000000248131

AUTHOR

Montserrat Rivero

0000-0002-5834-1559

showing 6 related works from this author

Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

2021

Abstract Background and Aims The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life. Methods Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16. Results A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% o…

Malemedicine.medical_specialtyustekinumabVedolizumab03 medical and health sciences0302 clinical medicineremissionColitis ulcerosaInternal medicineUstekinumabHumansMedicineProspective StudiesRegistriesInfusions IntravenousAdverse effectreal-world evidenceAcademicSubjects/MED00260ulcerative colitisTofacitinibresponsebiologybusiness.industryRemission InductionC-reactive proteinGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuation030220 oncology & carcinogenesisCohortbiology.proteindurabilityOriginal ArticleColitis UlcerativeFemaleMonoclonal antibodies030211 gastroenterology & hepatologyUstekinumabbusinessAnticossos monoclonalsmedicine.drug
researchProduct

Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.

2020

This is the peer reviewed version of the following article: Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. Journal of Gastroenterology and Hepatology (2020): 29 April, which has been published in final form at https://doi.org/10.1111/jgh.15084. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions

MaleTime FactorsDiseaseInflammatory bowel diseaseInflammatory bowel diseasesurgeryAnti-TNFBiological Factors0302 clinical medicineAnti-TNF Immunosuppressants Inflammatory bowel disease SurgeryCrohn DiseaseimmunosuppressantsRisk Factorsanti‐TNFGastroenterologyAge FactorsMiddle AgedUlcerative colitisNatural history030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleImmunosuppressive AgentsCohort studyAdultmedicine.medical_specialtyMedicinaDisease-Free Survival03 medical and health sciencesEarly surgeryYoung AdultGastrointestinal Agentsinflammatory bowel diseaseInternal medicinemedicineHumansSurvival analysisRetrospective StudiesHepatologybusiness.industryTumor Necrosis Factor-alphamedicine.diseasedigestive system diseasesInfliximabImmunosuppressantsSurgeryColitis Ulcerativebusiness
researchProduct

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study

2021

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and…

Crohn’s diseasemedicine.medical_specialtyPopulationDiseaseInflammatory bowel diseasedigestive systemArticle03 medical and health sciences0302 clinical medicineInterquartile rangeinflammatory bowel diseaseInternal medicineEpidemiologyMedicineeducationCrohn’s disease epidemiology incidence inflammatory bowel disease ulcerative colitisulcerative colitisCrohn's diseaseeducation.field_of_studybusiness.industryIncidence (epidemiology)RGeneral Medicinemedicine.diseaseUlcerative colitisdigestive system diseasesCrohn's disease030220 oncology & carcinogenesisincidenceMedicine030211 gastroenterology & hepatologyepidemiologybusiness
researchProduct

Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) y de la Confederación de Asociaciones de Enfermedad …

2018

Resumen Objetivos Establecer recomendaciones para el manejo de los aspectos psicologicos de los pacientes con enfermedad inflamatoria intestinal (EII). Metodos Se llevo a cabo una reunion con un grupo de expertos en EII formado por medicos, psicologos, enfermeras y representantes de pacientes. Se presentaron resultados de: 1) un grupo focal previo, 2) encuestas a medicos y pacientes y 3) una revision sistematica sobre instrumentos de cribado de ansiedad y depresion. Se realizo una discusion guiada sobre los aspectos psicologicos y emocionales mas importantes en EII, los criterios de derivacion apropiados y situaciones a evitar. Se selecciono el instrumento validado mas aplicable a la practi…

03 medical and health sciences0302 clinical medicineHepatologybusiness.industry030220 oncology & carcinogenesisGastroenterologyMedicine030211 gastroenterology & hepatologybusinessHumanitiesGastroenterología y Hepatología
researchProduct

Novel Probiotic Bifidobacterium longum subsp. infantis CECT 7210 Strain Active against Rotavirus Infections

2011

ABSTRACT Rotavirus is the leading cause of severe acute gastroenteritis among children worldwide. It is well known that breast-feeding and vaccination afford infants protection. Since breast-feeding has drastically decreased in developed countries, efforts have been focused on the potential use of probiotics as preventive agents. In this study, a novel Bifidobacterium longum subsp. infantis strain was isolated from infant feces and selected, based on its capacity to inhibit in vitro rotavirus Wa replication (up to 36.05% infectious foci reduction) and also to protect cells from virus infection (up to 48.50% infectious foci reduction) in both MA-104 and HT-29 cell lines. Furthermore, studies…

DNA BacterialRotavirusFood SafetyBifidobacterium longummedicine.drug_classMolecular Sequence DataAntibioticsVirus Replicationmedicine.disease_causeApplied Microbiology and BiotechnologyRotavirus InfectionsVirusCell LineMicrobiologylaw.inventionFecesMiceProbioticfluids and secretionslawRotavirusAntibiosismedicineAnimalsHumansFecesBifidobacteriumMice Inbred BALB CEcologybiologyProbioticsInfantSequence Analysis DNAbiology.organism_classificationVirologyVaccinationFood MicrobiologyBifidobacteriumFood ScienceBiotechnologyApplied and Environmental Microbiology
researchProduct

Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicen…

2019

Abstract Background and Aims Primary sclerosing cholangitis [PSC] is usually associated with inflammatory bowel disease [IBD]. An increased risk of malignancies, mainly colorectal cancer [CRC] and cholangiocarcinoma [CCA], has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics and management of PSC in IBD patients, and the factors associated with malignancies. Methods PSC-IBD patients were identified from the Spanish ENEIDA registry of GETECCU. Additional data were collected using the AEG-REDCap electronic data capture tool. Results In total, 277 PSC-IBD patients were included, with an incidence rate of 61 PSC cases per 100 000 IBD patient-years, 69.7% …

AdultMalemedicine.medical_specialtyendocrine system diseasesColorectal cancerCholangitis SclerosingRisk AssessmentGastroenterologyInflammatory bowel diseasedigestive systemPrimary sclerosing cholangitisCholangiocarcinomaBile Ducts ExtrahepaticRisk FactorsInterquartile rangeinflammatory bowel diseaseInternal medicineHumansMedicineRetrospective Studiesbusiness.industryPrimary sclerosing cholangitisHazard ratiodigestive oral and skin physiologyGastroenterologyRetrospective cohort studyGeneral MedicineOdds ratioMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseSurvival AnalysisUlcerative colitisdigestive system diseasesPatient Care ManagementBile Ducts IntrahepaticSpainFemalePrimary sclerosing cholangitis inflammatory bowel disease malignancyColorectal Neoplasmsbusinessmalignancy
researchProduct